- Case report
- Open Access
- Open Peer Review
Redo-redo aortic root replacement with a mechanical valved conduit in a patient with von Willebrand's disease: Case report
© Shaikhrezai et al; licensee BioMed Central Ltd. 2010
- Received: 1 June 2010
- Accepted: 13 August 2010
- Published: 13 August 2010
A 40 year-old female, with a history of cardiac surgery for congenital aortic valve stenosis and von Willebrand's disease (VWD) presented with increasing shortness of breath due to mixed aortic valve dysfunction. With a paucity of such cases in the literature, we describe the successful outcome of a patient with VWD who underwent elective redo-redo aortic root replacement with a mechanical valved conduit. She was given a three-month trial of warfarin pre-operatively to evaluate the extent of bleeding risk. Her post-operative course was uneventful and she was discharged home after six days.
- International Normalise Ratio
- Fresh Freeze Plasma
- Aortic Valve Stenosis
- Aortic Valve Disease
- Congenital Bicuspid Aortic Valve
VWD is an autosomal dominant bleeding diathesis with an incidence of 2-3% in the general population. The disease is characterised by a partial quantitative decrease of qualitatively normal von Willebrand factor (VWF) and Factor VIII (FVIII) . Recently researchers have reported that the increased shear stress resultant from a stenotic valve causes mechanical disruption and cleavage of VWF by ADAMTS-13, a metalloprotease enzyme that cleaves VWF, during passage through a stenotic orifice affecting the molecular conformation of large VWF multimers [2, 3]. There is a small and evolving literature regarding the management of patients with VWD undergoing cardiac surgery. Our patient received a trial of warfarin preoperatively which is a challenging decision in the context of VWD disease. We performed Redo-redo aortic valve replacement with a mechanical valved conduit. The surgical procedure accompanied by haematologist and anaesthetist input is discussed as well.
A 40 year-old female with type-I VWD and factor XII deficiency - a combination of haemostatic defects known as 'San Diego variant'- presented with exertional shortness of breath, tiredness and dizzy spells. Her basal FVIII/VWF: ristocetin cofactor and VWF Ag levels were 0.46 IU/ml and 0.40 IU/ml respectively.
At the age of 25 years, she had undergone a homograft aortic valve replacement (AVR) for congenital bicuspid aortic valve disease and severe aortic stenosis. Soon after surgery the implanted homograft became infected with Streptococcus Viridans causing vegetations and a paravalvular leak resulted in a re-do homograft AVR four months later. After the second operation she developed complete heart block and a permanent pacemaker was implanted. During these first two cardiac operations she received Haemate P concentrate (CSL Behring,UK Ltd) which is a plasma-derived FVIII concentrate rich in VWF, with a ratio of FVIII:C to VWF ristocetin cofactor of 1:2.2 and no major bleeding occurred. Since that time the patient had not suffered from major bleeding.
Regular follow-up in 2008 revealed that the implanted aortic homograft was degenerating. A trans-thoracic echocardiogram demonstrated mixed aortic valve disease with severe transvalvular regurgitation and a peak gradient of 59 mmHg accompanied by LV dilatation at 6.4 cm. LV systolic function was preserved with no hypertrophy and a mobile linear structure in the outflow tract suggesting prolapse of the cusp. A contrast computed tomography (CT) of the chest confirmed dilatation of the ascending aorta to 5 cm and it was appropriate to consider ascending aorta root replacement with a mechanical valved conduit. To evaluate whether the administration of vitamin K antagonists might pose bleeding problems post-operatively, she was warfarinised pre-operatively for a period of three months with an International Normalised Ratio (INR) range 2.0-3.0. After the trial period of warfarin had demonstrated no significant bleeding episodes, cardiac surgery was planned.
Pre- and post-operative hematological parameters
Activated partial thromboplastin time (APTT)
0.5 - 1.5 IU/ml
Factor IX: C
Factor XII assay
25 - 250 U/dl
FVIII/VWF: ristocetin cofactor assay
0.42 - 1.22 IU/ml
Two chest drains were removed safely on day one when the total blood loss was 2250 ml. In total, four units of packed red blood cells; three units of FFP and two units of platelets were given, in view of coagulopathy and anaemia. VWF levels were maintained above 100% throughout the operation and remained above 100% for over 5 days post-operatively without the need for exogenous factor administration beyond those already stated peri-operatively. Thromboprophylaxis using unfractionated heparin (25000 IU/2 ml) 5000 IU three times a day subcutaneously was commenced on post-operative day (POD) one and then she was warfarinised the same day aiming for an INR range of 2.0-3.0. Her post-operative course was uneventful and she was discharged home on POD 6 when her INR was within the therapeutic range. The patient was very well and asymptomatic six weeks later at a follow up visit with no bleeding or thrombotic events reported.
Due to a previous satisfactory response to FVIII/VWF concentrate and contraindication of desmopressin in patients with cardiac insufficiency because of fluid retention , FVIII/VWF concentrate was chosen as the treatment of choice to prevent peri- and post-operative bleeding. The replacement therapy can be monitored by factor assays performed in a specialist haemostasis laboratory . Such assays require a turnaround time of approximately one hour and are essential to enable optimal control of factor levels and dosing.
Clinically bleeding severity correlates with a reduction of VWF ristocetin cofactor and FVIII:C. Generally it is preferable to avoid anticoagulation in patients with VWD due to increased risk of bleeding. However in view of the patient's young age and previous homograft root replacement it was felt unwise to consider further, potentially multiple, redo homograft root replacements, and a mechanical valve was the prosthesis of choice. Our pre-operative evaluation of the patient required a 3-month period of observation whilst on warfarin to ensure that anti-coagulation could be controlled without major problems.
Our case demonstrates that complex cardiac surgery can be performed in patients with underlying congenital coagulopathy, and that a successful outcome requires close multidisciplinary cooperation in terms of planning and monitoring peri-operative factor replacement therapy, the dilemma regarding the type of prosthetic valve and the level of anticoagulation required post-operatively.
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Cameron CB, Kobrinsky N: Perioperative management of patients with von Willebrand's disease. Can J Anaesth. 1990, 37 (3): 341-7. 10.1007/BF03005587.View ArticlePubMedGoogle Scholar
- Yoshida K, Tobe S, Kawata M: Acquired von Willebrand disease type IIA in patients with aortic valve stenosis. Ann Thorac Surg. 2006, 81: 1114-6. 10.1016/j.athoracsur.2005.01.023.View ArticlePubMedGoogle Scholar
- Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, Ruggeri ZM: Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation. 2000, 102: 1290-5.View ArticlePubMedGoogle Scholar
- Joint Formulary Committee, British National Formulary: 2009, London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 58Google Scholar
- Gerling V, Lahpor JR, Buhre W: Peri-operative management of an adult patient with type 2N von Willebrand's disease scheduled for coronary artery bypass graft. Anaesthesia. 2007, 62 (4): 405-8. 10.1111/j.1365-2044.2007.05001.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.